Skip to main content
. 2015 Nov 2;112(46):E6321–E6330. doi: 10.1073/pnas.1519388112

Fig. S3.

Fig. S3.

Plk4 overexpression does not affect the type of tumor arising from heterozygous loss of p53. (A) Fold change in Plk4 mRNA in the lungs of Plk4 OE; ERT-Cre;Centrin-GFP;p53f/+ mice compared with control ERT-Cre;Centrin-GFP;p53f/+ mice. Measurements were taken at 2 mo after tamoxifen treatment. Bars represent the mean, and error bars indicate SEM. n = 4 mice with Plk4 OE and n = 4 mice without Plk4 OE. *P < 0.05; P value of unpaired t test calculated on the mean values from four independent measurements. (B) Percentage of centrosome amplification within cells expressing Centrin 1-GFP in the lung of Plk4 OE;ERT-Cre;Centrin-GFP;p53f/+ mice and control ERT-Cre;Centrin-GFP;p53f/+ mice. Measurements were taken at 2 mo after tamoxifen treatment. Bars represent the mean, and error bars indicate SEM. n = 6 mice with Plk4 OE and n = 4 mice without Plk4 OE. A minimum of 116 centrin-positive cells were counted for each data point. ns, P value > 0.05; P value of unpaired t test calculated on the mean values from four independent measurements. (C) Tumor-free survival and tumor spectrum of Plk4 OE;ERT-Cre;Centrin-GFP;p53f/+ mice and control ERT-Cre;Centrin-GFP;p53f/+ mice after 2 mo of feeding with food containing tamoxifen. At each event, the location and tumor type are described using a color code. (D) H&E-stained sections of tumors developed in Plk4 OE;ERT-Cre;Centrin-GFP;p53f/+ mice (mammary gland carcinoma, squamous cell carcinoma, and neuroblastoma within spleen) and in ERT-Cre;Centrin1-GFP;p53f/+ control mice (rhabdomyosarcoma). (E) Fold change in Plk4 mRNA in the lungs of Plk4 OE;ERT-Cre;Centrin-GFP;p53f/f mice compared with control ERT-Cre;Centrin-GFP;p53f/f mice. Measurements were taken at 2 mo after tamoxifen treatment. Bars represent the mean, and error bars indicate SEM. n = 5 mice with Plk4 OE and n = 4 mice without Plk4 OE. *P < 0.05; P value of unpaired t test calculated on the mean values from four and five independent measurements. (F) Representative immunofluorescence image of a lung section from a Plk4 OE;ERT-Cre;Centrin-GFP;p53f/f mouse after tamoxifen treatment. (G) Percentage of centrosome amplification within cells expressing Centrin 1-GFP in lungs of Plk4 OE;ERT-Cre;Centrin1-GFP;p53f/f mice and in control ERT-Cre;Centrin1-GFP;p53f/f mice. Measurements were taken at 2 mo after tamoxifen treatment. Bars represent the mean, and error bars indicate SEM. n = 5 mice with Plk4 OE and n = 4 mice without Plk4 OE. ***P < 0.001; P value of unpaired t test calculated on the mean values from four and five independent measurements. A minimum of 101 centrin-positive cells were counted for each animal. (H) Image of a thymic lymphoma developed in a Plk4 OE;ERT-Cre;Centrin-GFP;p53f/f mouse fed with tamoxifen. The dotted line highlights the tumor. (I) Percentage of Centrin 1-GFP–positive cells in individual thymic lymphomas. Tumors were from 15 ERT-Cre;Centrin-GFP;p53f/f animals and 14 Plk4 OE;ERT-Cre;Centrin1-GFP;p53f/f animals. A minimum of 40 centrin-positive cells were analyzed for each tumor.